Last reviewed · How we verify

NCT04470128

A Study Evaluating the Efficacy and Safety of HSK21542 Injection for Analgesia in Subjects Undergoing Colonoscopy

Completed Phase 2 Last updated 21 February 2023
What this trial tests

Phase 2 trial testing Stage I: HSK21542 0.5 μg/kg in Analgesia in 180 participants. Completed in 30 January 2021.

Timeline
19 August 2020
Primary endpoint
28 December 2020
30 January 2021

Quick facts

Lead sponsorHaisco Pharmaceutical Group Co., Ltd.
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment180
Start date19 August 2020
Primary completion28 December 2020
Estimated completion30 January 2021
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Haisco Pharmaceutical Group Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Analgesia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center, randomized, two-stage, phase II clinical study .The main objective is to evaluate the safety and tolerability of HSK21542 injection for analgesia in patients undergoing colonoscopy, and, combining the pharmacodynamic (PD) and pharmacokinetic (PK) characteristics

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Analgesia

Currently open trials in the same condition.

Other Haisco Pharmaceutical Group Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04470128.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing